Handelsavisen
prelaunch
Companies Healthcare RDNT.O
RD
RDNT.O NASDAQ Pharmaceuticals

RadNet Inc

$66,80
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
2,9 %
ROE
-1,3 %
Net margin
-0,7 %
Debt / equity
0,98
Beta
52w range
Volume
Day range
Prev close
$65,94
Open
$65,42
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

RadNet Inc operates in the healthcare sector, specifically within the Pharmaceuticals & Medical Research business sector, generating revenue through its classified activity in Pharmaceuticals.

Business. RadNet Inc (RDNT.O) is a healthcare company operating within the pharmaceuticals and medical research sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceutical activities.

Classification66 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target89,75

Analyst recommendations

8 analysts · consensus Buy
Buy8
Hold0
Sell0
12-month price target
89,75
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
8 analysts · indicative
Ownership
Principal Global Investors (Equity)
largest disclosed fund holder
Profitability
-1,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RDNT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RDNT.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    RadNet Inc (RDNT.O) is a healthcare company operating within the pharmaceuticals and medical research sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceutical activities.

    Classification66 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    (a) RadNet Inc maintains a capital structure characterized by significant leverage, with long-term debt of $1.06 billion against total equity of $1.09 billion, resulting in a debt-to-equity ratio of 0.98. The company holds $767.2 million in cash and equivalents, but the risk assessment flags that net cash is negative after subtracting total debt, indicating a medium liquidity risk profile. Total assets stand at $3.76 billion, while total liabilities are $2.40 billion.

    (b) Profitability metrics indicate operational challenges, with a return on equity of -1.3% and a return on assets of -0.38%. The company reported a net income loss of $18.7 million despite generating an operating income of $62.0 million, suggesting significant non-operating expenses or interest costs impacting the bottom line. Operating cash flow remains positive at $298.8 million, providing a buffer against the net income deficit.

    Key takeaways
    • RadNet generates $2.04 billion in revenue but reports a net loss of $18.7 million, driven by high leverage and interest expenses.
    • The company holds $767.2 million in cash but carries $1.06 billion in long-term debt, resulting in a negative net cash position.
    • Analyst sentiment is overwhelmingly positive, with a mean recommendation of 1.62 and a mean price target of $89.75.
    • Return on equity is negative at -1.3%, reflecting the impact of debt and net losses on shareholder value.
    • Operating cash flow is robust at $298.8 million, providing liquidity support despite the net income deficit.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Revenue grew 11.5% year-over-year to $2.04 billion in fiscal 2026, demonstrating consistent top-line expansion.

    Gross profit increased to $430.6 million in fiscal 2026, indicating improved cost of goods sold management.

    The company maintained a current ratio of 1.76, suggesting adequate short-term liquidity to meet obligations.

    Dilution risk is assessed as low, providing relative stability for existing shareholders regarding equity value erosion.

    BEAR CASE · 3

    Free cash flow turned deeply negative at -$44.0 million, reflecting significant cash burn and operational inefficiency.

    Long-term debt rose to $1.09 billion, increasing financial leverage and interest burden on the balance sheet.

    Credit risk is flagged as high, indicating potential difficulties in meeting debt obligations or securing financing.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-10
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $575.6M, +22,1% YoY; Operating income +0,8% YoY.

    Revenue$575.6M+22,1 % YoY
    Operating income-$23.9M+0,8 % YoY
    Net income-$33.5M+11,8 % YoY
    Free cash flow-$49.7M−15,3 % YoY
    EPS
    Operating cash flow$79.0M+90,4 % YoY
    Financials
    Income statement
    Revenue$575.6M
    Gross profit$186.8M
    Operating income-$23.9M
    Net income-$33.5M
    Margins
    Gross margin32.4%
    Operating margin-4.2%
    Net margin-5.8%
    FCF margin-8.6%
    Balance sheet
    Total assets$3.89B
    Total liabilities$2.80B
    Total equity$1.08B
    Cash & equivalents$455.3M
    Long-term debt$1.09B
    Cash flow
    Operating cash flow$79.0M
    CapEx-$69.9M
    Free cash flow-$49.7M
    SBC
    P&L flow · revenue → net income
    Revenue $575.6MOperating costs $599.5MTax $9.6MNet income $33.5M
    Highlights
    • Revenue $575.6M, +22,1% YoY
    • Operating income +0,8% YoY
    • Net income +11,8% YoY
    • Free cash flow −15,3% YoY
    • Net margin -5.8%

    Valuation TTM

    Market price
    $66,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.36B
    Net cash
    -$297.3M
    Current ratio
    Debt / equity
    1.0
    ROA
    -0.4%
    ROE
    -1.3%
    Cash conversion
    -2106.0%
    CapEx / revenue
    -9.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships105 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries105
    EX21:032d2a742a1cEX21:032d2a742a1cSubsidiarie97%
    EX21:07c28573466cEX21:07c28573466cSubsidiarie97%
    EX21:0bb8f28c0daaEX21:0bb8f28c0daaSubsidiarie97%
    EX21:0d3cfc6272efEX21:0d3cfc6272efSubsidiarie97%
    EX21:101a6ffc5f27EX21:101a6ffc5f27Subsidiarie97%
    EX21:11c80f26490dEX21:11c80f26490dSubsidiarie97%
    EX21:127443fd8c3aEX21:127443fd8c3aSubsidiarie97%
    EX21:12aa4872ea98EX21:12aa4872ea98Subsidiarie97%
    EX21:168d4ffed674EX21:168d4ffed674Subsidiarie97%
    EX21:1da665008866EX21:1da665008866Subsidiarie97%
    EX21:207dff4b72c0EX21:207dff4b72c0Subsidiarie97%
    EX21:2169faa4a579EX21:2169faa4a579Subsidiarie97%
    EX21:26864ee88567EX21:26864ee88567Subsidiarie97%
    EX21:2a70205d8917EX21:2a70205d8917Subsidiarie97%
    EX21:2c6794855332EX21:2c6794855332Subsidiarie97%
    EX21:2d9259f01d76EX21:2d9259f01d76Subsidiarie97%
    EX21:2decbf78d96fEX21:2decbf78d96fSubsidiarie97%
    EX21:30ab8105e0eaEX21:30ab8105e0eaSubsidiarie97%
    EX21:30d28c81216eEX21:30d28c81216eSubsidiarie97%
    EX21:350bbbd7ce6dEX21:350bbbd7ce6dSubsidiarie97%
    EX21:3ab11d1abba7EX21:3ab11d1abba7Subsidiarie97%
    EX21:41289803a375EX21:41289803a375Subsidiarie97%
    EX21:438b6bf059a8EX21:438b6bf059a8Subsidiarie97%
    EX21:449555250fafEX21:449555250fafSubsidiarie97%
    EX21:453f2d3bd0c7EX21:453f2d3bd0c7Subsidiarie97%
    EX21:4afa816f41f1EX21:4afa816f41f1Subsidiarie97%
    EX21:4f20642cb951EX21:4f20642cb951Subsidiarie97%
    EX21:519928c6f8f7EX21:519928c6f8f7Subsidiarie97%
    EX21:52403741ac6fEX21:52403741ac6fSubsidiarie97%
    EX21:541eea244defEX21:541eea244defSubsidiarie97%
    EX21:54f636961ec0EX21:54f636961ec0Subsidiarie97%
    EX21:575fe3b9b1e6EX21:575fe3b9b1e6Subsidiarie97%
    EX21:5ba6783cfa9bEX21:5ba6783cfa9bSubsidiarie97%
    EX21:5ef9fbb40680EX21:5ef9fbb40680Subsidiarie97%
    EX21:614a1f6db1c2EX21:614a1f6db1c2Subsidiarie97%
    EX21:618eb5658b3aEX21:618eb5658b3aSubsidiarie97%
    EX21:65f48e96b2adEX21:65f48e96b2adSubsidiarie97%
    EX21:671ccd71b9bfEX21:671ccd71b9bfSubsidiarie97%
    EX21:67b9367547b0EX21:67b9367547b0Subsidiarie97%
    EX21:68b185952979EX21:68b185952979Subsidiarie97%
    EX21:6be3e24c31cbEX21:6be3e24c31cbSubsidiarie97%
    EX21:6bf0696940cfEX21:6bf0696940cfSubsidiarie97%
    EX21:6cde22e2bbadEX21:6cde22e2bbadSubsidiarie97%
    EX21:6e695c917383EX21:6e695c917383Subsidiarie97%
    EX21:706e8beb4f1cEX21:706e8beb4f1cSubsidiarie97%
    EX21:730dc228269dEX21:730dc228269dSubsidiarie97%
    EX21:7380d953207cEX21:7380d953207cSubsidiarie97%
    EX21:7acaca89f108EX21:7acaca89f108Subsidiarie97%
    EX21:816209ceb261EX21:816209ceb261Subsidiarie97%
    EX21:82b7a050162aEX21:82b7a050162aSubsidiarie97%
    EX21:890155959d02EX21:890155959d02Subsidiarie97%
    EX21:8929190d0448EX21:8929190d0448Subsidiarie97%
    EX21:8932a899a1adEX21:8932a899a1adSubsidiarie97%
    EX21:8cdd89fcfb8dEX21:8cdd89fcfb8dSubsidiarie97%
    EX21:8e08c54ccf8fEX21:8e08c54ccf8fSubsidiarie97%
    EX21:916d0a1697e2EX21:916d0a1697e2Subsidiarie97%
    EX21:921f2c815418EX21:921f2c815418Subsidiarie97%
    EX21:9d43a8cb29aeEX21:9d43a8cb29aeSubsidiarie97%
    EX21:9dc4fe5dc91cEX21:9dc4fe5dc91cSubsidiarie97%
    EX21:9edaafaa99d6EX21:9edaafaa99d6Subsidiarie97%
    EX21:a20a31f71b5dEX21:a20a31f71b5dSubsidiarie97%
    EX21:a6f1927e2403EX21:a6f1927e2403Subsidiarie97%
    EX21:a877c5655ae0EX21:a877c5655ae0Subsidiarie97%
    EX21:aac41be7f965EX21:aac41be7f965Subsidiarie97%
    EX21:ad4867e6091dEX21:ad4867e6091dSubsidiarie97%
    EX21:b076118ed259EX21:b076118ed259Subsidiarie97%
    EX21:b1dc8554cb1fEX21:b1dc8554cb1fSubsidiarie97%
    EX21:b695fed900dcEX21:b695fed900dcSubsidiarie97%
    EX21:b8ee381ad8b9EX21:b8ee381ad8b9Subsidiarie97%
    EX21:bda460047ea2EX21:bda460047ea2Subsidiarie97%
    EX21:bdcbefcf7eb7EX21:bdcbefcf7eb7Subsidiarie97%
    EX21:bf12fbc61291EX21:bf12fbc61291Subsidiarie97%
    EX21:c0c95192e463EX21:c0c95192e463Subsidiarie97%
    EX21:c18074c75f45EX21:c18074c75f45Subsidiarie97%
    EX21:c517495b938fEX21:c517495b938fSubsidiarie97%
    EX21:c5a92183ee25EX21:c5a92183ee25Subsidiarie97%
    EX21:c6f5fcedd8b9EX21:c6f5fcedd8b9Subsidiarie97%
    EX21:c7e7c2fa76ebEX21:c7e7c2fa76ebSubsidiarie97%
    EX21:cae791f74e1bEX21:cae791f74e1bSubsidiarie97%
    EX21:cd51d7d8826fEX21:cd51d7d8826fSubsidiarie97%
    EX21:cd84e47d736aEX21:cd84e47d736aSubsidiarie97%
    EX21:ce56f71224b8EX21:ce56f71224b8Subsidiarie97%
    EX21:ce7639d2cae5EX21:ce7639d2cae5Subsidiarie97%
    EX21:cea3d2dbe5e3EX21:cea3d2dbe5e3Subsidiarie97%
    EX21:cfbe9ff453ceEX21:cfbe9ff453ceSubsidiarie97%
    EX21:d0562e339527EX21:d0562e339527Subsidiarie97%
    EX21:d12547efe97bEX21:d12547efe97bSubsidiarie97%
    EX21:d39b57e5ea79EX21:d39b57e5ea79Subsidiarie97%
    EX21:d9112fbcacafEX21:d9112fbcacafSubsidiarie97%
    EX21:db93f766aac3EX21:db93f766aac3Subsidiarie97%
    EX21:dbf860e23577EX21:dbf860e23577Subsidiarie97%
    EX21:e29812135a02EX21:e29812135a02Subsidiarie97%
    EX21:e5ac7a5bd683EX21:e5ac7a5bd683Subsidiarie97%
    EX21:e6384575f2d4EX21:e6384575f2d4Subsidiarie97%
    EX21:e676d854e6efEX21:e676d854e6efSubsidiarie97%
    EX21:e9ac948cbdbcEX21:e9ac948cbdbcSubsidiarie97%
    EX21:eb18d5cc0cefEX21:eb18d5cc0cefSubsidiarie97%
    EX21:ec8ec0e3a753EX21:ec8ec0e3a753Subsidiarie97%
    EX21:f09a19896442EX21:f09a19896442Subsidiarie97%
    EX21:f3cd651b0a8bEX21:f3cd651b0a8bSubsidiarie97%
    EX21:f96166422ba5EX21:f96166422ba5Subsidiarie97%
    EX21:fbb288f2d526EX21:fbb288f2d526Subsidiarie97%
    EX21:fcb7a1e342feEX21:fcb7a1e342feSubsidiarie97%
    EX21:fdfe70dccf48EX21:fdfe70dccf48Subsidiarie97%
    EX21:ff74347f8b19EX21:ff74347f8b19Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,51
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    8
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,51
    Revenueno estimateno estimate2,5B USD
    Operating incomeno estimateno estimate123,8M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy5
    Hold0
    Sell0
    Strong sell0
    12-month price target$89,75 · Median $93,50
    Low $65,00High $100,00
    Operating income · consensus123,8M USD
    EPS surprise
    −20,2 %
    reported vs consensus · miss
    Revenue surprise
    −18,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$65,00
    Mean$89,75
    Median$93,50
    High$100,00
    Spot$66,80
    +34.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin2,9 %Below median
    Net Margin-0,7 %Below median
    ROE-1,3 %Below median
    Capex / Rev-9,9 %Below median
    D/E0,98Bottom quartile
    Cash Conv-21,06Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 128 055 sh11 exercises4 insiders
    • Berger Howard GDirector, President, CEO · Stock Option (right to buy) → Common StockDisposed 25 992 @ $18,64exercise · 2026-05-05
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 2 493exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 742exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 4 987exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 6 237exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 7 481exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 8 727exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 12 466exercise · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Employee Stock Option (right to buy) → Common StockDisposed 16 831exercise · 2026-03-10
    • Katz David JeffreyEVP and Chief Legal Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 396 @ $29,44exercise · 2025-12-10
    • STOLPER MARKEVP, Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 35 703 @ $6,07exercise · 2025-12-10

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Assets
      net_income / total_assets
    • Return On Equity
      net_income / total_equity
    Source documents
    • RadNet, Inc. Market data — financials · 2026-07-10
    • RadNet Inc Market data — analyst estimates · 2026-07-10
    • RadNet Inc Market data — ESG · 2026-07-10
    • RadNet Inc HA canonical relationships · 2026-07-10

    Ownership & reference

    Top holders

    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,03 %$62M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,03 %$0M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,03 %$50M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,02 %$77M
    • Invesco QQQ TrustFunds · as of 2026-03-310,01 %$91M
    • Jennison Associates LLCInvestment Managers · as of 2026-03-310,01 %$20M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$566M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$45M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,01 %$50M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$67M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$532M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,01 %$24M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$43M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$26M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$96M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$42M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$148M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$27M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$23M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$22M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$48M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$8M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$4M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$2M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$12M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$3M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$1M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • David ScultPresident & CEO

    Insider activity

    Net selling0 buys · 12 sellsnet -$8,4M13 insiders · last 365d
    • SWARTZ DAVID LDirector · Common StockSold 2 699 @ $53,89$145K · 2026-06-18
    • Wesdorp CornelisPres & CEO, Digital Health · Common StockSold 4 750 @ $58,11$276K · 2026-06-16
    • Berger Howard GDirector, President, CEO · Common StockOther 90 · 2026-06-16
    • Forthuber Stephen MPres & CEO-Eastern Operations · Common StockSold 24 214 @ $57,79$1,4M · 2026-06-15
    • Forthuber Stephen MPres & CEO-Eastern Operations · Common StockSold 19 853 @ $58,61$1,2M · 2026-06-15
    • SPURLOCK GREGORY E.Director · Common StockOther 2 946 · 2026-06-02
    • SWARTZ DAVID LDirector · Common StockOther 2 946 · 2026-06-02
    • Jacobs Laura PastreDirector · Common StockOther 2 946 · 2026-06-02
    • Levitt Lawrence LDirector · Common StockOther 2 946 · 2026-06-02
    • Berger Howard GDirector, President, CEO · Common StockOther 25 992 @ $18,64$484K · 2026-05-05
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockSold 9 554 @ $61,84$591K · 2026-03-19
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockSold 5 346 @ $62,82$336K · 2026-03-19
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockSold 100 @ $63,59$6K · 2026-03-19
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 7 000 · 2026-03-19
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockSold 14 200 @ $62,12$882K · 2026-03-18
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockSold 800 @ $62,72$50K · 2026-03-18
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 5 919 @ $61,72$365K · 2026-03-16
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 6 237 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 3 742 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 4 987 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 7 481 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 8 727 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 12 466 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 2 493 · 2026-03-10
    • Sorensen Alma GregoryDirector, Chief Strategy Officer · Common StockOther 16 831 · 2026-03-10

    Short positioning

    10.0Mshares short+0.3% vs prior
    11.38days to cover
    72.3%short of daily vol
    6fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RDNT.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    RDNTEX21:032EX21:07cEX21:0bbEX21:0d3EX21:101EX21:11cEX21:127EX21:12aEX21:168EX21:1daPharmaceutical
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Revenue (annual): USD 2.04BUnknown
    • Operating income (annual): USD 61.99MUnknown
    • Cash & equivalents (annual): USD 767.22MUnknown
    • Net income (annual): USD -18.65MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -0Unknown
    • Shareholders' equity (annual): USD 1.09BUnknown
    • Total liabilities (annual): USD 2.4BUnknown
    • Pre-tax income (annual): USD 31.91MUnknown
    • Long-term debt (annual): USD 1.09BUnknown
    • Shares outstanding (annual): 77.4MUnknown
    • Total operating expenses (annual): USD 1.98BUnknown
    • Current assets (annual): USD 1.03BUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -0Unknown
    • Operating cash flow (annual): USD 298.82MUnknown
    • Current liabilities (annual): USD 586.76MUnknown
    • Total assets (annual): USD 3.76BUnknown
    • Total assets (annual): USD 3.29BUnknown
    • EPS (basic) (annual): USD-PER-SHARES 0Unknown
    • Shares outstanding (annual): 74.04MUnknown
    • Current assets (annual): USD 1.02BUnknown
    • Long-term debt (annual): USD 1.02BUnknown
    • Operating income (annual): USD 104.62MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES 0Unknown
    • Shareholders' equity (annual): USD 902.31MUnknown
    Showing 24 of 32 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-18 00:00 UTCINSIDER9 insider transactions — 2026-06 · net sell $3.0M
    2026-06-18 00:00 UTCINSIDER9 insider transactions — 2026-06 · net sell $3.0M
    2026-06-18INSIDERSWARTZ DAVID L sold 2.7k sh — Director ~$145k
    2026-06-16INSIDERWesdorp Cornelis sold 4.8k sh — Pres & CEO, Digital Health ~$276k
    2026-06-16INSIDERBerger Howard G transacted 90 sh — Director, President, CEO
    2026-06-15INSIDERForthuber Stephen M sold 24.2k sh — Pres & CEO-Eastern Operations ~$1.40M
    2026-06-15INSIDERForthuber Stephen M sold 19.9k sh — Pres & CEO-Eastern Operations ~$1.16M
    2026-06-10FILINGFORM 8-K →
    2026-06-04FILINGCURRENT REPORT →
    2026-06-03FILINGCURRENT REPORT →
    2026-06-02INSIDERSPURLOCK GREGORY E. transacted 2.9k sh — Director
    2026-06-02INSIDERSWARTZ DAVID L transacted 2.9k sh — Director
    2026-06-02INSIDERJacobs Laura Pastre transacted 2.9k sh — Director
    2026-06-02INSIDERLevitt Lawrence L transacted 2.9k sh — Director
    2026-05-11FILING10-Q filing →
    2026-05-11FILINGCURREMT REPORT →
    2026-05-10 05:00 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 575.6M · Net USD -33.5M
    2026-05-05 00:00 UTCINSIDER2 insider transactions — 2026-05 · net buy $484k 1 derivative
    2026-05-05 00:00 UTCINSIDER2 insider transactions — 2026-05 · net buy $484k 1 derivative
    2026-05-05INSIDERBerger Howard G transacted 26.0k sh — Director, President, CEO ~$484k
    2026-05-05INSIDERBerger Howard G disposed of 26.0k sh Stock Option (right to buy) — Director, President, CEO
    2026-03-19 00:00 UTCINSIDER33 insider transactions — 2026-03 · net sell $2.2M 8 derivative
    2026-03-19 00:00 UTCINSIDER33 insider transactions — 2026-03 · net sell $2.2M 8 derivative
    2026-03-19INSIDERSorensen Alma Gregory sold 9.6k sh — Director, Chief Strategy Officer ~$591k
    2026-03-19INSIDERSorensen Alma Gregory sold 5.3k sh — Director, Chief Strategy Officer ~$336k
    2026-03-19INSIDERSorensen Alma Gregory sold 100 sh — Director, Chief Strategy Officer ~$6k
    2026-03-19INSIDERSorensen Alma Gregory transacted 7.0k sh — Director, Chief Strategy Officer
    2026-03-18INSIDERSorensen Alma Gregory sold 14.2k sh — Director, Chief Strategy Officer ~$882k
    2026-03-18INSIDERSorensen Alma Gregory sold 800 sh — Director, Chief Strategy Officer ~$50k
    2026-03-16INSIDERSorensen Alma Gregory transacted 5.9k sh — Director, Chief Strategy Officer ~$365k
    2026-03-10INSIDERSorensen Alma Gregory transacted 6.2k sh — Director, Chief Strategy Officer
    2026-03-10INSIDERSorensen Alma Gregory transacted 3.7k sh — Director, Chief Strategy Officer
    2026-03-10INSIDERSorensen Alma Gregory transacted 5.0k sh — Director, Chief Strategy Officer
    2026-03-10INSIDERSorensen Alma Gregory transacted 7.5k sh — Director, Chief Strategy Officer
    2026-03-10INSIDERSorensen Alma Gregory transacted 8.7k sh — Director, Chief Strategy Officer
    2026-03-10INSIDERSorensen Alma Gregory transacted 12.5k sh — Director, Chief Strategy Officer
    2026-03-10INSIDERSorensen Alma Gregory transacted 2.5k sh — Director, Chief Strategy Officer
    Showing the 40 most recent of 71 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage